Elaine K.  Sorg net worth and biography

Elaine Sorg Biography and Net Worth

SVP of AbbVie
Elaine Sorg joined AbbVie in 2012 as the vice president of U.S. Immunology, where she was responsible for Humira®, AbbVie’s flagship brand.  Her responsibilities were expanded in 2016 to include AbbVie’s U.S. Oncology business, and again in 2019 to the role of President, U.S. Immunology and Patient Services.  She leads a combined organization of more than 2,000 employees and contractors.  Humira has achieved record-breaking performance under Elaine’s leadership, with five consecutive years of sales growth in excess of $1 billion, of which three years were in excess of $2 billion in growth. The product has become the best-selling prescription medicine in the U.S., with 2018 U.S. net sales exceeding $13 billion.  Venclexta® net sales performance significantly accelerated under Ms. Sorg’s leadership, driven by successful Relapsed Refractory CLL and AML launches, and new levels of patient starts.  Skyrizi®, which launched in April, 2019 for the treatment of moderate to severe plaque psoriasis has exceeded expectations, being rated as the best launch in the US Dermatology market, as well as the best pharmaceutical launch in the US bio-pharmaceutical market by several analysts including Steve Scala of SG Cowen.  Rinvoq® is in the early stages of launch for the treatment of moderate to severe rheumatoid arthritis. Likewise, the Patient Services organization, with the flagship HUMIRA Complete® program, is recognized as the best in the pharmaceutical industry by several external parties, including Raymond James, as well as in testimony delivered to Congress by Dr. Mark Fendrick (University of Michigan). 

Ms. Sorg has more than 29 years of experience leading complex businesses in the biopharmaceutical industry across multiple therapeutic areas including:  Immunology, Cardiovascular, Neuroscience, Diabetes, Infectious Disease, Women’s Health, and Oncology.  In the course of that leadership Ms. Sorg has accumulated an impressive list of launches including 13 new products, significant product line extensions, and additional indications for HUMIRA including Ulcerative Colitis, Pediatric Crohn’s Disease, Hidradenitis Suppurativa and Uveitis, as well as HUMIRA Citrate Free in the US market.

Prior to joining AbbVie, she enjoyed a 23-year career in senior management with Eli Lilly & Co., where she led numerous teams across the pharmaceutical value chain.  She is an exceptional leader, with a proven ability to unite diverse stakeholders around a common vision to achieve peak performance.   Her leadership is best represented by her team’s ability to deliver innovative solutions that create and maximize value for patients, as well as her legacy of developing next-generation leaders at all levels.  Elaine was honored with the Most Powerful and Influential Woman in Illinois Award from the Illinois Diversity Council in April, 2014.  She was also recognized as one of the Top 50 Influencers in Health Care by MM&M in 2016.  In 2017, she was honored with the AbbVie New Pharma Leader award. 

Elaine is passionate about the wellbeing of the patient and regards them as the North Star in all she does.  She served as the Employee Giving Campaign Chair and Co-Chairperson for Abbvie in 2016 and 2015, respectively, and as the Eli Lilly’s Corporate United Way Chairman from 2000-2001.  She has also held board appointments with several charitable organizations over the past decade.  In 2019 Elaine was appointed to the BIO Board as AbbVie’s representative.  She served as a member of the IBM Watson Health Advisory Board from 2015-2017. 

Elaine graduated from Purdue University School of Pharmacy and Pharmaceutical Sciences, and holds certificates from Harvard Business School and The University of Chicago Booth School of Management.

What is Elaine K. Sorg's net worth?

The estimated net worth of Elaine K. Sorg is at least $5.96 million as of April 25th, 2023. Ms. Sorg owns 35,330 shares of AbbVie stock worth more than $5,956,285 as of June 14th. This net worth approximation does not reflect any other assets that Ms. Sorg may own. Learn More about Elaine K. Sorg's net worth.

How do I contact Elaine K. Sorg?

The corporate mailing address for Ms. Sorg and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Elaine K. Sorg's contact information.

Has Elaine K. Sorg been buying or selling shares of AbbVie?

Elaine K. Sorg has not been actively trading shares of AbbVie during the last quarter. Most recently, Elaine K. Sorg sold 6,130 shares of the business's stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $165.00, for a transaction totalling $1,011,450.00. Following the completion of the sale, the senior vice president now directly owns 35,330 shares of the company's stock, valued at $5,829,450. Learn More on Elaine K. Sorg's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Elaine K. Sorg Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/25/2023Sell6,130$165.00$1,011,450.0035,330View SEC Filing Icon  
4/17/2023Sell7,499$161.67$1,212,363.3335,330View SEC Filing Icon  
4/3/2023Sell15,002$160.03$2,400,770.0642,829View SEC Filing Icon  
3/1/2023Sell15,003$155.00$2,325,465.0042,829View SEC Filing Icon  
12/13/2021Sell6,458$125.85$812,739.30View SEC Filing Icon  
3/1/2021Sell8,440$108.61$916,668.4026,035View SEC Filing Icon  
See Full Table

Elaine K. Sorg Buying and Selling Activity at AbbVie

This chart shows Elaine K Sorg's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89


3,933,662 shs

Average Volume

5,477,690 shs

Market Capitalization

$297.71 billion

P/E Ratio


Dividend Yield